
NICE recommends triplet regimen for relapsed multiple myeloma
NICE has recommended Ninlaro (ixazomib) with lenalidomide and dexamethasone as an option relapsed or refractory multiple myeloma (RRMM) in adults who have received two or three lines of therapy. Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has been used to treat… Read More















